Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv13
  2. Study Status, Referencesv12
  3. Study completion date changed from estimate of Dec 2015 to Jul 2016
    • Trial status: Active, Not Recruiting to Completed
    v11
  4. Study completion date: Jun 2015 to Dec 2015v10
  5. Primary completion date changed from estimate of Jun 2009 to Feb 2010
    • Study completion date: Jun 2009 to Jun 2015
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jun 2009
    • Secondary endpoints: 1 to 2
    • Site details revised at 2 of 2 sites
    v7
  3. Primary endpoint revisedv6 Show 5 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoint revised
    • Study title shortened, about 7 words
    • Study arms: 0 to 1
    • Study description shortened, about 1 word
  4. Study description revisedv5
  5. Secondary endpoint revisedv4 Show 4 more changesShow less
    • Primary endpoint revised
    • Eligibility criteria expanded, about 5 words
    • Study description shortened, about 1 word
    • Study title expanded, about 4 words
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess if argon plasma coagulation (APC) is a safe and well tolerated treatment method for anal intraepithelial neoplasia (AIN) grade 2/3 in HIV-positive men having sex with men (MSM).
Trial Details
NCT Number NCT00428285
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, CIHR Canadian HIV Trials Network
Conditions
(from sponsor)		 Anus Neoplasms, HIV Infections
Related terms Anus Neoplasms, HIV Infections
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov